Inventiva (NASDAQ:IVA) Shares Gap Up - Still a Buy?

Key Points

• Inventiva shares jumped 12%, opening at $3.51 versus a prior close of $3.29 and later trading around $3.665, though they remained below the 50-day and 200-day moving averages.
• Analyst sentiment is broadly positive: MarketBeat reports a consensus “Buy” rating and an average price target of $15.14, despite one “Sell” rating.
• The clinical-stage biopharmaceutical company reported a quarterly loss of $0.14 per share and $0.75 million in revenue. Its lead drug candidate, lanifibranor, is in late-stage development for MASH, while institutional investors own 19.06% of the stock.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report)'s share price gapped up before the market opened on Wednesday. The stock had previously closed at $3.29, but opened at $3.51. Inventiva shares last traded at $3.6650, with a volume of 400,933 shares traded.

Analyst Upgrades and Downgrades

IVA has been the subject of several analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Inventiva in a research note on Friday, July 17th. Cantor Fitzgerald assumed coverage on Inventiva in a research note on Friday, July 17th. They issued an "overweight" rating on the stock. Guggenheim upped their target price on Inventiva from $11.00 to $14.00 and gave the company a "buy" rating in a report on Tuesday, September 15th. Finally, Piper Sandler reaffirmed an "overweight" rating on shares of Inventiva in a research report on Wednesday, September 16th. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $15.14.

Inventiva Stock Up 12.0%

The firm has a 50 day simple moving average of $4.38 and a 200 day simple moving average of $4.71.

Inventiva (NASDAQ:IVA - Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter. The company had revenue of $0.75 million for the quarter. On average, equities analysts expect that Inventiva S.A. Sponsored ADR will post -0.86 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Engineers Gate Manager LP increased its stake in shares of Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company's stock worth $269,000 after buying an additional 43,280 shares during the period. Persistent Asset Partners Ltd purchased a new stake in Inventiva during the 4th quarter valued at $603,000. Seven Fleet Capital Management LP bought a new stake in Inventiva in the 1st quarter worth $1,111,000. Eventide Asset Management LLC bought a new stake in Inventiva in the 4th quarter worth $1,155,000. Finally, Propel Bio Management LLC purchased a new position in shares of Inventiva in the fourth quarter valued at about $4,650,000. 19.06% of the stock is currently owned by institutional investors.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva's lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.